Alkermes plc Stock News

ALKS, $31.48, Market Capitalization: $5.

Alkermes (ALKS) receives final award in arbitration proceedings with partner Janssen. It also raises its financial outlook for 2023.

Alkermes (ALKS) reports encouraging first-quarter results, wherein both earnings and revenues beat estimates. This is due to strong growth in commercial execution of its proprietary products, Lybalvi

Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street

Alkermes (ALKS) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to earnings of $0.12 per share a year ago.

Alkermes shares have surged in the past six months, owing to strong sales performance of its new drug Lybalvi and its decision to separate the oncology unit.

Alkermes shares have surged in the past six months, owing to strong sales performance of its new drug Lybalvi and its decision to separate the oncology unit.

Alkermes' (ALKS) earnings and sales beat estimates in the fourth quarter of 2022.

Alkermes' (ALKS) earnings and sales beat estimates in the fourth quarter of 2022.

Alkermes (ALKS) delivered earnings and revenue surprises of 180% and 6.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Alkermes plc (NASDAQ:ALKS ) Q4 2022 Earnings Conference Call February 16, 2023 8:00 AM ET Company Participants Sandra Coombs - Senior Vice President of Investor Relations and Corporate Affairs Todd Ni

Alkermes (ALKS) delivered earnings and revenue surprises of 180% and 6.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Devoid of marketed drugs, investors' will focus on Verona Pharma's (VRNA) lead pipeline candidate when it reports its fourth-quarter earnings.

Let's look at the four biotech/drug companies slated to release quarterly results on Feb 16.

Exelixiss' EXEL) partner Sairopa gets FDA clearance for its IND application for the oncology drug ADU-1805, a potential best-in-class monoclonal antibody for adults with advanced solid tumors.